TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03245073

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action observation therapy
Description: The normal human movement will be recorded and than the patients will be watched them.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Strengthening and stretching exercise programme focuses on hip and knee muscles

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Strengthening and stretching exercise programme focuses on hip and knee muscles
Study: NCT02529787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxirazole
Description: 1 capsule contains 60 mg Dexlansoprazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexilant
Description: 1 capsule contains 60 mg Dexlansoprazole
Study: NCT05883891

Intervention type: DIAGNOSTIC_TEST
Intervention: prothrombin time
Description: Prothrombin time at value at diagnosis was used to assess the presence of a correlation with Lille score at day 7 and therefore wether it could predict response to medical treatment.
Study: NCT00620412

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus rhamnosus
Description: 2 capsules by mouth 2 times a day for 28 days. Each capsule contains 1x10\^10 LGG organisms.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo control
Description: 2 capsules by mouth twice a day for 28 days

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Influenza Virus Vaccine Live, Intranasal
Description: intranasal spray, 0.1ml per nostril, one time dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Virus Vaccine Live, Intranasal
Description: intranasal spray, 0.1ml per nostril, one time dose
Study: NCT01490437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2 IV over 10 minutes on D1 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 70 mg/m2 IV over 60 minutes on D1 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 4 mg bid PO from D-1 to D2 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamins
Description: Folic acid 350 ug - 600 ug daily from D-7 daily vitamin B12 1,000 ug every 9 weeks from D-7
Study: NCT02370875

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magstim RapidStim2
Description: Application of repetitious transcranial magnetic stimulation (TMS) pulses using Magstim RapidStim2 to a specific brain target at predefined stimulation parameters.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Magstim RapidStim2
Description: Same procedure as real rTMS without stimulating the cerebral cortex.
Study: NCT03048929

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Typhoid Vi Polysaccharide Vaccine
Description: Salmonella typhi capsular polysaccharide vaccine (Typhoid Vi Polysaccharide Vaccine): Each dose of 0.5ml Salmonella typhi capsular polysaccharide vaccine (Sanofi Pasteur, SA) is formulated to contain 25μg of purified Vi polysaccharide in a colorless isotonic phosphate buffered saline (pH 7±0.3), 4.150mg of sodium chloride, 0.065mg of disodium phosphate, 0.023mg of monosodium phosphate and 0.5ml of sterile water for injection. It is indicated for use by humans aged 2 years and older for protection against typhoid fever.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo injection will consist of 0.5mL of saline.
Study: NCT01173991

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Carbohydrate counting training
Description: Carbohydrate counting was taught during 4-5 individual sessions with a dietician and a diabetologist.

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Carbohydrate counting training
Description: Carbohydrate counting was taught during 4-5 individual sessions with a dietician and a diabetologist.
Study: NCT01219010

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: 15mg/kg IV infusion every 3 weeks for 4 cycles. If applicable extended dosing of 15 mg/kg IV infusion every 4 weeks for up to 2 years.
Study: NCT02354937

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK1265744 30 mg
Description: White to almost white coated oval tablets with unit dose strength of 30 mg for oral administrations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 30 mg
Description: White to almost white coated oval tablets with unit dose strength of 30 mg for oral administrations.
Study: NCT04992819

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chronobiological Approach Nutrition Model
Description: In the intervention group, a label containing the time of expressed breastmilk will be affixed. In the milk preparation room, breast milk will be stored in a separate refrigerator as 08:00-19:59 day milk and 20:00-07:59 night milk.
Study: NCT01029132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: galantamine
Description: 8 mg/day (4 mg bid) during the first 4 weeks, up to a maximum of 24 mg/day (12 mg bid) at intervals of 4 weeks, from 16 to 24 mg/day based on the patient's tolerability

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: galantamine
Description: 8 mg/day (4 mg bid) during the first 4 weeks, up to a maximum of 24 mg/day (12 mg bid) at intervals of 4 weeks, from 16 to 24 mg/day based on the patient's tolerability
Study: NCT04370080

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride 38%
Description: Dental caries arrest medication
Study: NCT03149081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boswellia
Description: Boswellia is an extract from frankincense
Study: NCT02514616

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic IPG and lead implant procedure
Description: EST placement

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Laparoscopic IPG and lead implant procedure
Description: EST placement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Electric Stimulation Therapy
Description: Device programming by the technician to deliver the EST system active (Treatment group) or no stimulation (Control group) for the following 12 weeks, at the 2 weeks visit.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Delayed Electric Stimulation Therapy
Description: Device programming by the technician to deliver the EST system no stimulation for the following 12 weeks at the 2 weeks visit. Active Electric Stimulation Therapy will be programmed at the 14 weeks visit.
Study: NCT01931657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone prior to Mirena

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo prior to Mirena insertion
Study: NCT02103998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thryoid hormone T4 + oral potassium iodide (KI) for 42 days
Description: Continuous infusion of 4 µg/Kg/day T4 with 30 µg/Kg/day oral potassium iodide (KI) for 42 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: D5W - 5% dextrose water
Description: Equivalent volume of infusion as study drug
Study: NCT03615196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: USB005 (aclerastide) Ophthalmic Solution
Description: Aclerastide (\[Nle3\]-Angiotensin II (1-7)) is aseptically formulated in USB005 Ophthalmic Solution for topical ophthalmic administration. Active pharmaceutical ingredient (API) levels ranging from 0.03% to 0.45% are formulated in a sterile vehicle consisting of 0.06% Sodium Phosphate Monobasic Anhydrous, USP; 3% Glycerol, USP; 1.4% Polyvinyl Alcohol, USP; and 0.5% Hydroxyethylcellulose (HEC 250 HHX), NF in Sterile Water for Injection, USP.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: USB005 (aclerastide) Ophthalmic Solution
Description: Aclerastide (\[Nle3\]-Angiotensin II (1-7)) is aseptically formulated in USB005 Ophthalmic Solution for topical ophthalmic administration. Active pharmaceutical ingredient (API) levels ranging from 0.03% to 0.45% are formulated in a sterile vehicle consisting of 0.06% Sodium Phosphate Monobasic Anhydrous, USP; 3% Glycerol, USP; 1.4% Polyvinyl Alcohol, USP; and 0.5% Hydroxyethylcellulose (HEC 250 HHX), NF in Sterile Water for Injection, USP.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: USB005 (aclerastide) Ophthalmic Solution
Description: Aclerastide (\[Nle3\]-Angiotensin II (1-7)) is aseptically formulated in USB005 Ophthalmic Solution for topical ophthalmic administration. Active pharmaceutical ingredient (API) levels ranging from 0.03% to 0.45% are formulated in a sterile vehicle consisting of 0.06% Sodium Phosphate Monobasic Anhydrous, USP; 3% Glycerol, USP; 1.4% Polyvinyl Alcohol, USP; and 0.5% Hydroxyethylcellulose (HEC 250 HHX), NF in Sterile Water for Injection, USP.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: USB005 (aclerastide) Ophthalmic Solution
Description: Aclerastide (\[Nle3\]-Angiotensin II (1-7)) is aseptically formulated in USB005 Ophthalmic Solution for topical ophthalmic administration. Active pharmaceutical ingredient (API) levels ranging from 0.03% to 0.45% are formulated in a sterile vehicle consisting of 0.06% Sodium Phosphate Monobasic Anhydrous, USP; 3% Glycerol, USP; 1.4% Polyvinyl Alcohol, USP; and 0.5% Hydroxyethylcellulose (HEC 250 HHX), NF in Sterile Water for Injection, USP.
Study: NCT02677883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptom-guided thoracentesis
Description: Arm II will undergo a standard of care therapeutic thoracentesis procedure. In this group, the procedure but will be stopped when the patient develops symptoms or when all the fluid has been removed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Symptom-guided thoracentesis
Description: Arm II will undergo a standard of care therapeutic thoracentesis procedure. In this group, the procedure but will be stopped when the patient develops symptoms or when all the fluid has been removed.
Study: NCT05151276

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile phone-based distance video education group
Description: Following the first interview, diabetes education videos created previously were sent to the mobile phones of the individuals in two episodes a week fashion. Video submission was completed in a total of four weeks. In the second interview, three months after the video submission had been completed, data collection forms were re-administered to the individuals, and blood analysis results were recorded.
Study: NCT00404469

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peritendinous corticosteroid injections
Description: 1 ml of40mg/ml methylprednisolone acetate at 0 and 4 weeks. 2 week observational

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: eccentric decline squat training
Description: eccentric decline unilateral squats performed twice daily. for 12 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: heavy slow resistance training
Description: Heavy slow resistance training for knee extensors. 3/week. total of 12 weeks
Study: NCT02797613

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Restricted Reporting
Description: An abbreviated version of the microbiology report indicating that growth is present and the physician should call the lab for further details if clinically important
Study: NCT01497223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCD290
Description: 1 Oral Dose Administration
Study: NCT00536419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Methylphenidate SODAS 0.3 mg/kg/day (day 1); 0.7 mg/kg/day (day 2); 1.0 mg/kg/day (days 3 and 4)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, daily dose, 4 days, oral administration
Study: NCT00713518

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5 mg ranibizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg PF-04523655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg PF-04523655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 mg PF-04523655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 mg PF-04523655
Study: NCT03352609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active rTMS with MagVenture MagPro double blind rTMS system
Description: 5 sessions of rTMS delivered with MagPro (MagVenture) double blind rTMS system delivered at 110% of resting motor threshold with 3000 pulses of 10hz stimulation (5s on, 10s off) per session.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Double blind MagPro system delivers sham condition by mimicking rTMS sound and delivering skin stimulus via TENS pads
Study: NCT00530972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a plus ribavirin adjusted to body weight
Description: PegInterferon 180 mcg/week, Adjusted body weight Ribavirin (1000 mg \<75 kg, 1200 mg \>75 kg)
Study: NCT02506244

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iRhythm ZIO XT Patch
Description: Single-lead ECG monitoring via a wearable patch

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iRhythm ZIO XT Patch
Description: Single-lead ECG monitoring via a wearable patch

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wristband by Amiigo
Description: Determines pulse rate using photoplethysmography.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wristband by Amiigo
Description: Determines pulse rate using photoplethysmography.
Study: NCT00669734

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Falimarev
Description: Given intratumorally or SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inalimarev
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC
Study: NCT01673542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine-Prilocaine 5%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DEXERYL
Study: NCT02917122

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active tDCS
Description: Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Patients will take Sertraline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sertraline
Description: Patients will take Sertraline.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham tDCS
Description: Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.
Study: NCT01075490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clonidine
Description: addition of 1 µg/kg of clonidine to bupivacaine 1 mg/kg as spinal anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clonidine
Description: addition of 1 µg/kg of clonidine to bupivacaine 1 mg/kg as spinal anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: clonidine
Description: equivalent volume of saline added to bupivacaine, 1 mg/kg as spinal anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: clonidine
Description: equivalent volume of saline added to bupivacaine, 1 mg/kg as spinal anesthesia
Study: NCT04053803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMR-687
Description: Oral administration of once daily IMR-687
Study: NCT01017302

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutenaous once weekly for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single subcutaneous dose in week 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5095932
Description: Escalating subcutaneous doses once weekly over a 4 weeks period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5095932
Description: Single subcutenaous dose in week 5
Study: NCT00224640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron chelating intervention
Description: Iron chelating intervention
Study: NCT00779350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline 100 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline 100 mg tablets
Study: NCT00422682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bsi-201 + topotecan
Description: 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bsi-201 + temozolomide
Description: 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bsi-201 + gemcitabine
Description: 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bsi-201 + carboplatin/paclitaxel
Description: 21 day cycle
Study: NCT02936804

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Dose Computed Tomography
Description: LDCT was performed at baseline and 2 rounds of biennial repeated LDCT. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 4 mm. The management of abnormal nodules including precision diagnosis by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), electromagnetic navigation bronchoscope (ENB) and peripheral biomarkers, and precision therapy by intraoperative frozen section guided lung resection and ENB radiofrequency ablation.
Study: NCT00476853

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HAART containing nevirapine
Description: Initially NVP 200 mg BID (400 mg per day) was compared to 400 mg BID and 200 mg OD NVP (600 mg per day). 400 mg/day versus 600 mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HAART containing nevirapine
Description: Initially NVP 200 mg BID (400 mg per day) was compared to 400 mg BID and 200 mg OD NVP (600 mg per day). 400 mg/day versus 600 mg/day.
Study: NCT02529969

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: curcumin

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02019095

Intervention type: OTHER
Intervention: Bronchoscopy for the sampling of bronchoalveolar lavage (BAL) fluid
Study: NCT02944487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucerastat
Description: Hard gelatin capsule for oral administration containing lucerastat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucerastat
Description: Hard gelatin capsule for oral administration containing lucerastat

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules
Study: NCT00105781

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise counseling
Study: NCT04180761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC)
Description: single dose application of hyperthermic intraperitoneal chemotherapy (HIPEC) at 42.5°C for 60 minutes after the gastrectomy
Study: NCT02212782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin 5mg
Description: Linagliptin 5mg once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin 5mg
Description: Linagliptin 5mg once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1029M 1200mg and Linagliptin 5mg
Description: Linagliptin 5mg 1 tablet once daily and DW1029M 300mg 2 tablets b.i.d for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1029M 1200mg and Linagliptin 5mg
Description: Linagliptin 5mg 1 tablet once daily and DW1029M 300mg 2 tablets b.i.d for 7 days
Study: NCT02094157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapered warfarin regimen
Description: This intervention is assigned to the experimental arm - Tapered warfarin regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bridged regimen Low-molecular-weight heparin
Description: This intervention is assigned to the active control arm - Bridged regimen
Study: NCT02267837

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrthoPulse™
Description: Patients carry out daily OrthoPulse™ treatments at home.
Study: NCT02401789

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implants (OsseospeedTM,EV Astra Tech System, DentsplyTM, Mölndal)
Study: NCT00395031

Intervention type: DRUG
Group type: OTHER
Intervention: Ziprasidone
Description: Ziprasidone dose of between 40 mg po bid to 160 mg po bid for 8 weeks
Study: NCT04431440

Intervention type: OTHER
Intervention: silver nanoparticles
Description: effect silver nanoparticles will be examined on multidrug resistant bacteria

Intervention type: OTHER
Intervention: silver nanoparticles
Description: effect silver nanoparticles will be examined on multidrug resistant bacteria
Study: NCT00645346

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBS glycoconjugate vaccine
Description: Study subjects will receive either GBS conjugate vaccine or placebo. Total study size is 65. Study subjects will be followed for a total of 12 months after their last vaccination.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive one dose of placebo
Study: NCT04078425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldosterone Antagonists
Description: aldosterone antagonist will be applied to patients of heart failure with preserved ejection fraction, level of the drug will be sampled before administration of the drug and follow up will be sampled after one month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldosterone Antagonists
Description: aldosterone antagonist will be applied to patients of heart failure with preserved ejection fraction, level of the drug will be sampled before administration of the drug and follow up will be sampled after one month
Study: NCT00787644

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone tablets; 30 mg/day for 2 weeks; then increased to 45 mg/day until week 12 (approximately 3 months)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo (inert tablet)
Study: NCT00296621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Glutamine
Description: L-Glutamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo